Astrazeneca

AstraZeneca is global innovation-driven biopharmaceutical company specialising in the discovery, development, manufacturing and marketing of prescription medicines that make a meaningful difference in healthcare. AstraZeneca discovers new medicines that are designed to improve the health and quality of life of patients around the world - medicines which are innovative, effective and which offer added benefits such as reduced side effects or better ways of taking the treatment. They also focus on getting the best from every medicine they make by exploring all the ways it can be used or improved. Their business strategy sets out their path to success in delivering great medicines to patients through innovative science and global excellence in development and commercialisation.
Type
Public
HQ
London, GB
Founded
1999
Employees
61,500 (est)+7%
Astrazeneca was founded in 1999 and is headquartered in London, GB

Key People at Astrazeneca

Pascal Soriot

Pascal Soriot

Executive Director and Chief Executive Officer
Ed Mathers

Ed Mathers

Team Member
Bahija Jallal

Bahija Jallal

Executive Vice President
Fiona Cicconi

Fiona Cicconi

Executive Vice President
Mark Mallon

Mark Mallon

Executive Vice President
Menelas Pangalos

Menelas Pangalos

Executive Vice President
Ruud Dobber

Ruud Dobber

Executive Vice President
Jeff Pott

Jeff Pott

General Counsel
Linda C. Bain

Linda C. Bain

USA/Canada Head - Global R&D Finance
Paul Hudson

Paul Hudson

President, AstraZeneca US and Executive Vice President
Marc Dunoyer

Marc Dunoyer

Executive Director, Chief Financial Officer
Katarina Ageborg

Katarina Ageborg

Chief Compliance Officer
Luke Miels

Luke Miels

Executive Vice President Global Product and Portfolio Strategy
Caroline Hempstead

Caroline Hempstead

Executive Vice President, Human Resources and Corporate Affairs (interim)
Pam Cheng

Pam Cheng

Executive Vice-President

Astrazeneca Locations

London, GB
Denver, US
Bangalore, IN
New Brunswick, US
Wilmington, US
Cincinnati, US
Roanoke, US
Hong Kong, HK
Shanghai, CN
Osaka, JP
Jackson, US
Wedel, DE
Derby, GB
Toledo, US
Gaithersburg, US
Dallas, US
Leiden, NL
Los Angeles, US
Albany, US
Durham, US

Astrazeneca Metrics

Astrazeneca Summary

Market capitalization

$70.6 B

Closing share price

$28.5
Astrazeneca's current market capitalization is $70.6 B.

Astrazeneca Financials

We estimate that Astrazeneca's revenue is £18.3 B in FY, 2015 which is 6.93% decrease from the previous period.
FY, 2013FY, 2014FY, 2015

Revenue

£16.9 B£19.6 B£18.3 B

Revenue growth, %

16.1%-6.9%

Cost of sales

£3.46 B£4.32 B£3.44 B

Gross profit

£13.4 B£15.3 B£14.8 B

Gross profit Margin, %

79.5%78.0%81.2%

Operating expense total

£11 B£13.7 B£11.8 B

    Astrazeneca Market Value History

    Astrazeneca Online Presence

    Astrazeneca News

    Astrazeneca Company Life

    You may also be interested in